Affordable Access

Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).

Authors
  • Dutkiewicz, S
  • Witeska, A
  • Stepień, K
Type
Published Article
Journal
International urology and nephrology
Publication Date
Jan 01, 1995
Volume
27
Issue
4
Pages
413–417
Identifiers
PMID: 8586513
Source
Medline
License
Unknown

Abstract

This part of our study presents results of laboratory evaluations in patients with BPH during treatment with prazosin and doxazosin. After 72 weeks serum PSA and PAP fell by 40.2% and 82%, respectively. Blood urea nitrogen concentration decreased by 28.5% and serum creatinine by 20.8%. The results confirm long-term favourable effects of the therapy of patients with BPH.

Report this publication

Statistics

Seen <100 times